SEC Comment Letter 0000000000-24-008236 to MetaVia Inc. (MTVA)
MetaVia Inc.
Date: July 22, 2024 · CIK: 0001638287 · Accession: 0000000000-24-008236
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280865
Letter
July 22, 2024 Hyung Heon Kim Chief Executive Officer NeuroBo Pharmaceuticals, Inc. 545 Concord Avenue, Suite 210 Cambridge, Massachusetts 02138 Re:NeuroBo Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed July 18, 2024 File No. 333-280865 Dear Hyung Heon Kim: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Joshua W. Damm
Show Raw Text
July 22, 2024
Hyung Heon Kim
Chief Executive Officer
NeuroBo Pharmaceuticals, Inc.
545 Concord Avenue, Suite 210
Cambridge, Massachusetts 02138
Re:NeuroBo Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed July 18, 2024
File No. 333-280865
Dear Hyung Heon Kim:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Joshua W. Damm